Cite
HARVARD Citation
Ramalingam, S. et al. (2022). JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Cancer. 128 (1), pp. 65-74. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ramalingam, S. et al. (2022). JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Cancer. 128 (1), pp. 65-74. [Online].